Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024894 | 1.00 | JAK2 (0.42) | JAK2JAK1GRM2OPRL1OPRM1 | |
| SCHEMBL3007706 | 1.00 | JAK2 (0.42) | JAK2JAK1GRM2OPRL1OPRM1 | |
| SCHEMBL3013405 | 0.86 | GRM2 (0.38) | JAK2JAK1GRM2OPRL1OPRM1 | |
| SCHEMBL3013412 | 0.86 | GRM2 (0.38) | JAK2JAK1GRM2OPRL1OPRM1 | |
| SCHEMBL3013407 | 0.86 | GRM2 (0.38) | JAK2JAK1GRM2OPRL1OPRM1 | |
| SCHEMBL3020023 | 0.83 | AKR1C1 (0.34) | PRNPPTGIRKMT2A | |
| SCHEMBL3007835 | 0.83 | AKR1C1 (0.34) | PRNPPTGIRKMT2A | |
| SCHEMBL3007830 | 0.83 | AKR1C1 (0.34) | PRNPPTGIRKMT2A | |
| SCHEMBL3017022 | 0.79 | GRM2 (0.38) | JAK2JAK1GRM2OPRL1OPRM1 | |
| SCHEMBL3017015 | 0.79 | GRM2 (0.38) | JAK2JAK1GRM2OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164825-B1 | DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8076324-B2 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A2, RYR2 | JAK2 4173/4885JAK1 3862/4885GRM2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.